Nicholson Bruce, Agarwala Sanjiv S
Division of Pain Medicine, Pain Specialists of Greater Lehigh Valley, Pennsylvania, USA.
J Opioid Manag. 2011 Jan-Feb;7(1):69-79. doi: 10.5055/jom.2011.0050.
Analgesics delivered via the oral route of administration (capsules, tablets, or solutions) are most commonly used to treat cancer breakthrough pain (BTP); however, the effectiveness of oral opioids may be limited by slow gastrointestinal absorption and first-pass metabolic effects. Although the limitations presented by oral opioid delivery are acknowledged and formulations and delivery systems that mirror the temporal characteristics of the majority of cancer BTP episodes are available, short-acting oral opioids are the accepted standard of care. The purpose of this review is to provide an overview of the different routes of opioid administration used in the treatment of cancer BTP and briefly discuss the characteristics of different delivery systems.
通过口服途径给药(胶囊、片剂或溶液)的镇痛药是治疗癌症爆发性疼痛(BTP)最常用的药物;然而,口服阿片类药物的有效性可能会受到胃肠道吸收缓慢和首过代谢效应的限制。尽管人们认识到口服阿片类药物给药存在局限性,并且有能够反映大多数癌症BTP发作时间特征的制剂和给药系统,但短效口服阿片类药物仍是公认的治疗标准。本综述的目的是概述用于治疗癌症BTP的阿片类药物不同给药途径,并简要讨论不同给药系统的特点。